Author: Brownson Norby Source: http://www.brownsonnorby.com/blog/fda-and-cbd/ Earlier this month, on April 9, 2018, FDA published a notice requesting comments from the public on the scheduling of cannabis-related substances (“Cannabis Plant and Resin; Extracts...
Authored By: Rod Kight 13 April 2018 The FDA is taking public comments on cannabinoids until April 23. It seeks information on abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use. I strongly...
Adam Detsky and Carlos Enrique Provencio of Wilson Elser write…… In November 2011, the governors of Washington and Rhode Island filed a petition with the U.S. Drug Enforcement Agency (DEA) asking that marijuana be reclassified as a Schedule II drug. Nearly...
Matt Maurer – Minden Gross
Jeff Hergot – Wildboer Dellelce LLP
Tim Morales – The Cannabis Industry Association Costa Rica
Elvin Rodríguez Fabilena
Carl L Rowley -Thompson Coburn LLP
Jerry Chesler – Chesler Consulting
Ian Stewart – Wilson Elser Moskowitz Edelman & Dicker LLP
Otis Felder – Wilson Elser Moskowitz Edelman & Dicker LLP
Lance Rogers – Greenspoon Marder – San Diego
Jessica McElfresh -McElfresh Law – San Diego
Tracy Gallegos – Partner – Fox Rothschild
Adam Detsky – Knight Nicastro
Dave Rodman – Dave Rodman Law Group
Peter Fendel – CMR Real Estate Network
Nate Reed – CMR Real Estate Network
Matthew Ginder – Greenspoon Marder
David C. Kotler – Cohen Kotler
William Bogot – Fox Rothschild
Valerio Romano, Attorney – VGR Law Firm, PC